Skip to main content
Erschienen in: Urolithiasis 3/2006

01.06.2006 | Original Paper

The effect of calcium channel blockers on stone regrowth and recurrence after shock wave lithotripsy

verfasst von: Kemal Sarica, Yener İnal, Sakip Erturhan, Faruk Yağci

Erschienen in: Urolithiasis | Ausgabe 3/2006

Einloggen, um Zugang zu erhalten

Abstract

We evaluated the possible effects of a calcium entry blocking agent “verapamil” on new stone formation and/or regrowth of residual fragments after shock wave lithotripsy (SWL) during long-term follow-up (>30 months) and compared the results with the success rates of adequate fluid intake. A total of 70 patients treated with SWL were randomly divided into three different groups, in the first two of which the patients received different preventive measures with respect to stone recurrence and/or regrowth. While 25 patients received a calcium channel blocking agent, verapamil hydrochloride, beginning 3 days before SWL and continued 4 weeks after the procedure, an additional 25 patients were put in an enforced fluid intake program and the remaining 20 patients received no specific medication and/or measure apart from close follow-up. Patients were followed regularly with respect to the clearance/regrowth of the residual fragments and that of new stone formation during long-term follow-up (within a mean follow-up of 30.4 months). The overall stone recurrence rate was 14% (10/70). Of the patients who became stone free (12/25, 48%) in group I, only one patient (1/12, 8.3%) showed a new stone formation during long-term follow-up. The figure was 40% (4/10) in group II patients and 55% (5/9) in group III patients receiving no specific medication. Regarding the residual stone fragments (<5 mm) after SWL, again high fluid intake was found to be the most effective on stone regrowth rates (2/13, 15.3%). Patients treated with verapamil also had acceptable regrowth rates (3/15, 20%). Finally, verapamil treatment significantly improved the clearance of residual fragments; while 7 out of 15 patients with residual fragments passed these particles successfully, (46.5%) in this group; these figures were 46% (6/13) and 18% (2/13) in the remaining groups. Residual fragments located in lower calyces demonstrated a poor clearance rate with higher regrowth rates. Verapamil administration was found to be effective enough to limit the regrowth of residual fragments and also to facilitate residual fragment clearance after SWL. Patients receiving this medication seemed to pass the retained fragments easily in a shorter time than the others.
Literatur
1.
Zurück zum Zitat Yu CC, Lee YH, Huang JK, Chen MT, Chen KK, Lin AT, Chang LS (1993) Long-term stone regrowth and recurrence rates after extracorporeal shock wave lithotripsy. Br J Urol 72(5 Pt 2):688–691PubMed Yu CC, Lee YH, Huang JK, Chen MT, Chen KK, Lin AT, Chang LS (1993) Long-term stone regrowth and recurrence rates after extracorporeal shock wave lithotripsy. Br J Urol 72(5 Pt 2):688–691PubMed
2.
Zurück zum Zitat Candau C, Saussine C, Lang H, Roy C, Faure F, Jacqmin D (2000) Natural history of residual renal stone fragments after ESWL. Eur Urol 37(1):18–22PubMedCrossRef Candau C, Saussine C, Lang H, Roy C, Faure F, Jacqmin D (2000) Natural history of residual renal stone fragments after ESWL. Eur Urol 37(1):18–22PubMedCrossRef
3.
Zurück zum Zitat Streem SB, Yost A, Mascha E (1996) Clinical implications of clinically insignificant store fragments after extracorporeal shock wave lithotripsy. J Urol 155(4):1186–1190PubMedCrossRef Streem SB, Yost A, Mascha E (1996) Clinical implications of clinically insignificant store fragments after extracorporeal shock wave lithotripsy. J Urol 155(4):1186–1190PubMedCrossRef
4.
Zurück zum Zitat Beck EM, Riehle RA Jr (1991) The fate of residual fragments after extracorporeal shock wave lithotripsy monotherapy of infection stones. J Urol 145(1):6–9; discussion 9–10 Beck EM, Riehle RA Jr (1991) The fate of residual fragments after extracorporeal shock wave lithotripsy monotherapy of infection stones. J Urol 145(1):6–9; discussion 9–10
5.
Zurück zum Zitat Newman DM, Lingeman JE (1989) Management of upper urinary tract calculi with extracorporeal shock-wave lithotripsy. Compr Ther 15(8):35–40PubMed Newman DM, Lingeman JE (1989) Management of upper urinary tract calculi with extracorporeal shock-wave lithotripsy. Compr Ther 15(8):35–40PubMed
6.
Zurück zum Zitat Pak CY (2004) Medical management of urinary stone disease. Nephron Clin Pract 98(2):c49–c53PubMedCrossRef Pak CY (2004) Medical management of urinary stone disease. Nephron Clin Pract 98(2):c49–c53PubMedCrossRef
7.
Zurück zum Zitat Preminger GM, Sakhaee K, Skurla C, Pak CYC (1985) Prevention of recurrent calcium stone formation with potassium citrate therapy in patients with distal renal tubular acidosis. J Urol 134:20–23PubMed Preminger GM, Sakhaee K, Skurla C, Pak CYC (1985) Prevention of recurrent calcium stone formation with potassium citrate therapy in patients with distal renal tubular acidosis. J Urol 134:20–23PubMed
8.
Zurück zum Zitat Tapaneya-Olarn W (2002) The optimal dose of potassium citrate in the treatment of children with distal renal tubular acidosis. J Med Assoc Thai 85(Suppl 4):S1143–S1149PubMed Tapaneya-Olarn W (2002) The optimal dose of potassium citrate in the treatment of children with distal renal tubular acidosis. J Med Assoc Thai 85(Suppl 4):S1143–S1149PubMed
9.
Zurück zum Zitat Tekin A (2002) Oral potassium citrate treatment for idiopathic hypocitraturia in children with calcium urolithiasis. J Urol 168(6):2572–2574PubMedCrossRef Tekin A (2002) Oral potassium citrate treatment for idiopathic hypocitraturia in children with calcium urolithiasis. J Urol 168(6):2572–2574PubMedCrossRef
10.
Zurück zum Zitat Soygür T (2002) Effect of potassium citrate therapy on stone recurrence and residual fragments after shock wave lithotripsy in şower caliceal urolithiasis: a randomized controlled trial. J Endourol 16(3):149–152PubMedCrossRef Soygür T (2002) Effect of potassium citrate therapy on stone recurrence and residual fragments after shock wave lithotripsy in şower caliceal urolithiasis: a randomized controlled trial. J Endourol 16(3):149–152PubMedCrossRef
11.
Zurück zum Zitat Cicerello E, Merlo F, Gambaro G, Maccatrozzo L, Fandella A, Baggio B, Anselmo G (1994) Effect of alkaline citrate therapy on clearance of residual renal stone fragments after extracorporeal shock wave lithotripsy in sterile calcium and infection nephrolithiasis patients. J Urol 151(1):5–9PubMed Cicerello E, Merlo F, Gambaro G, Maccatrozzo L, Fandella A, Baggio B, Anselmo G (1994) Effect of alkaline citrate therapy on clearance of residual renal stone fragments after extracorporeal shock wave lithotripsy in sterile calcium and infection nephrolithiasis patients. J Urol 151(1):5–9PubMed
12.
Zurück zum Zitat Grossman E, Messerli FH (2002) Cardiac effects of calcium antagonists in hypertension. In: Epstein M (ed) Calcium antagonists in clinical medicine. Hanley and Belfus, Philadelphia, pp 207–228 Grossman E, Messerli FH (2002) Cardiac effects of calcium antagonists in hypertension. In: Epstein M (ed) Calcium antagonists in clinical medicine. Hanley and Belfus, Philadelphia, pp 207–228
13.
Zurück zum Zitat Frishman WH (1994) Current status of calcium channel blockers. Curr Probl Cardiol 19:637–688PubMedCrossRef Frishman WH (1994) Current status of calcium channel blockers. Curr Probl Cardiol 19:637–688PubMedCrossRef
14.
Zurück zum Zitat Mason RP, Marche P, Hintze TH (2003) Novel vascular biology of third-generation L-type calcium channel antagonists: ancillary actions of amlodipine. Arterioscler Thromb Vasc Biol 23(12):2155–2163PubMedCrossRef Mason RP, Marche P, Hintze TH (2003) Novel vascular biology of third-generation L-type calcium channel antagonists: ancillary actions of amlodipine. Arterioscler Thromb Vasc Biol 23(12):2155–2163PubMedCrossRef
15.
Zurück zum Zitat Hoskin DH, Erickson SD, van der Berg CJ, Wilson DM, Smith LH (1983) The stone clinic effect in patients with idiopathic calcium nephrolithiasis. J Urol 13:1115–1118 Hoskin DH, Erickson SD, van der Berg CJ, Wilson DM, Smith LH (1983) The stone clinic effect in patients with idiopathic calcium nephrolithiasis. J Urol 13:1115–1118
16.
Zurück zum Zitat Borghi L, Meschi T, Amato F, Briganti A, Navarini A, Giannini A (1996) Urine volume, water and recurrences in idiopathic calcium nephrolithiasis. A 5-year randomized prospective study. J Urol 155:839–843PubMedCrossRef Borghi L, Meschi T, Amato F, Briganti A, Navarini A, Giannini A (1996) Urine volume, water and recurrences in idiopathic calcium nephrolithiasis. A 5-year randomized prospective study. J Urol 155:839–843PubMedCrossRef
17.
Zurück zum Zitat Epstein M (1992) Calcium antagonists and renal protection: current status and future perspectives. Arch Intern Med 152:1573–1584PubMedCrossRef Epstein M (1992) Calcium antagonists and renal protection: current status and future perspectives. Arch Intern Med 152:1573–1584PubMedCrossRef
18.
Zurück zum Zitat Epstein M (2002) Calcium antagonists and the kidney: implications for renal protection. In: Epstein M (ed) Calcium antagonists in clinical medicine. Hanley and Belfus, Philadelphia, pp 629–664 Epstein M (2002) Calcium antagonists and the kidney: implications for renal protection. In: Epstein M (ed) Calcium antagonists in clinical medicine. Hanley and Belfus, Philadelphia, pp 629–664
19.
Zurück zum Zitat Epstein M, Loutzenhiser R (1990) Potential applicability of calcium antagonists as renal protective agents. In: Epstein M, Loutzenhiser R (eds) Calcium antagonists and the kidney. Hanley and Belfus, Philadelphia, pp 275–298 Epstein M, Loutzenhiser R (1990) Potential applicability of calcium antagonists as renal protective agents. In: Epstein M, Loutzenhiser R (eds) Calcium antagonists and the kidney. Hanley and Belfus, Philadelphia, pp 275–298
20.
Zurück zum Zitat Hayashi K, Ozawa Y, Saruta T, Epstein M (2002) Renal hemodynamic effects of calcium antagonists. In: Epstein M (ed) Calcium antagonists in clinical medicine. Hanley and Belfus, Philadelphia, pp 559–578 Hayashi K, Ozawa Y, Saruta T, Epstein M (2002) Renal hemodynamic effects of calcium antagonists. In: Epstein M (ed) Calcium antagonists in clinical medicine. Hanley and Belfus, Philadelphia, pp 559–578
21.
Zurück zum Zitat Strohmaier WL, Koch J, Balk N, Wilbert DM, Bichler KH (1994) Limitation of shock-wave-induced renal tubular dysfunction by nifedipine. Eur Urol 25(2):99–104PubMed Strohmaier WL, Koch J, Balk N, Wilbert DM, Bichler KH (1994) Limitation of shock-wave-induced renal tubular dysfunction by nifedipine. Eur Urol 25(2):99–104PubMed
22.
Zurück zum Zitat Strohmaier WL, Bichler KH, Koch J, Balk N, Wilbert DM (1993) Protective effect of verapamil on shock wave induced renal tubular dysfunction. J Urol 150(1):27–29PubMed Strohmaier WL, Bichler KH, Koch J, Balk N, Wilbert DM (1993) Protective effect of verapamil on shock wave induced renal tubular dysfunction. J Urol 150(1):27–29PubMed
23.
Zurück zum Zitat Strohmaier WL, Abelius A, Billes I, Grossmann T, Wilbert DM, Bichler KH (1994) Verapamil limits shockwave induced renal tubular damage in vivo. J Endourol 8(4):269–273PubMed Strohmaier WL, Abelius A, Billes I, Grossmann T, Wilbert DM, Bichler KH (1994) Verapamil limits shockwave induced renal tubular damage in vivo. J Endourol 8(4):269–273PubMed
24.
Zurück zum Zitat Strohmaier WL, Witte B, Nelde HJ (1994) Influence of nifedipine on stone formation and renal function in cholesterol-induced nephrolithiasis in rats. Urol Int 52(2):87–92PubMed Strohmaier WL, Witte B, Nelde HJ (1994) Influence of nifedipine on stone formation and renal function in cholesterol-induced nephrolithiasis in rats. Urol Int 52(2):87–92PubMed
25.
Zurück zum Zitat Sarica K, Bakir K, Yağci F, Topçu O, Akbay C, Sayin N, Korkmaz C (1999) Limitation of possible enhanced crystal deposition by verapamil in renal parenchyma after shock wave application in rabbit model. J Endourol 13(5):343–347PubMedCrossRef Sarica K, Bakir K, Yağci F, Topçu O, Akbay C, Sayin N, Korkmaz C (1999) Limitation of possible enhanced crystal deposition by verapamil in renal parenchyma after shock wave application in rabbit model. J Endourol 13(5):343–347PubMedCrossRef
26.
Zurück zum Zitat Jan CR, Chen WC, Wu SN, Tseng CJ (1998) Nifedipine, verapamil and diltiazem block shock-wave-induced rises in cytosolic calcium in MDCK cells. Chin J Physiol 41(4):181–188PubMed Jan CR, Chen WC, Wu SN, Tseng CJ (1998) Nifedipine, verapamil and diltiazem block shock-wave-induced rises in cytosolic calcium in MDCK cells. Chin J Physiol 41(4):181–188PubMed
27.
Zurück zum Zitat Iguchi M, Ikegami M, Kiwamoto H, Umekawa T, Ishikawa Y, Kohri K, Kurita T (1993) Effect of verapamil on urinary calcium and oxalate excretion in renal stone formers. Hinyokika Kiyo 39(5):425–431PubMed Iguchi M, Ikegami M, Kiwamoto H, Umekawa T, Ishikawa Y, Kohri K, Kurita T (1993) Effect of verapamil on urinary calcium and oxalate excretion in renal stone formers. Hinyokika Kiyo 39(5):425–431PubMed
28.
Zurück zum Zitat Baggio B, Gambaro G, Marchini F, Cicerello E, Borsatti A (1986) Effect of nifedipine on urinary calcium and oxalate excretion in renal stone formers. Nephron 43(3):234–235PubMed Baggio B, Gambaro G, Marchini F, Cicerello E, Borsatti A (1986) Effect of nifedipine on urinary calcium and oxalate excretion in renal stone formers. Nephron 43(3):234–235PubMed
29.
Zurück zum Zitat Bichler KH, Strohmaier WL, Schanz F, Nelde HJ, Gaiser I, Schulze E, Schreiber M (1985) Effect of calcium antagonists (nifedipine) on nephrocalcinosis and calcium excretion in the rat. Urol Int 40(1):13–21PubMedCrossRef Bichler KH, Strohmaier WL, Schanz F, Nelde HJ, Gaiser I, Schulze E, Schreiber M (1985) Effect of calcium antagonists (nifedipine) on nephrocalcinosis and calcium excretion in the rat. Urol Int 40(1):13–21PubMedCrossRef
30.
Zurück zum Zitat Yaman Ö, Sarica K, Özer G, Soygür T, Kutsal O, Yaman LS, Göğüş O (1996) Protective effect of verapamil on renal histology following shock wave application in rabbit model. J Endourol 10(4):329–333PubMed Yaman Ö, Sarica K, Özer G, Soygür T, Kutsal O, Yaman LS, Göğüş O (1996) Protective effect of verapamil on renal histology following shock wave application in rabbit model. J Endourol 10(4):329–333PubMed
31.
Zurück zum Zitat Sarica K, Özer G, Soygür T, Yaman Ö, Özer E, Üstün H, Yaman LS, Göğüş O (1997) Preservation of shock-wave-induced renal histologic changes by dermatan sulphate. Urology 49(1):145–150PubMedCrossRef Sarica K, Özer G, Soygür T, Yaman Ö, Özer E, Üstün H, Yaman LS, Göğüş O (1997) Preservation of shock-wave-induced renal histologic changes by dermatan sulphate. Urology 49(1):145–150PubMedCrossRef
32.
Zurück zum Zitat Akbay C, Sayin C, Sarica K, Soygür T, Sabuncuoğlu B (1998) Effect of verapamil on rabbit renal tissue after shock wave lithotripsy: an ultrastructural approach. Electron Microsc IV:493–494 Akbay C, Sayin C, Sarica K, Soygür T, Sabuncuoğlu B (1998) Effect of verapamil on rabbit renal tissue after shock wave lithotripsy: an ultrastructural approach. Electron Microsc IV:493–494
33.
Zurück zum Zitat Sarica K, Bakir K, Yağci F, Erbağci A, Topçu O, Uysal O (1999) Unilateral testicular torsion: protective effect of Verapamil on contralateral testicular histology. Urol Int 62(3):159–163PubMedCrossRef Sarica K, Bakir K, Yağci F, Erbağci A, Topçu O, Uysal O (1999) Unilateral testicular torsion: protective effect of Verapamil on contralateral testicular histology. Urol Int 62(3):159–163PubMedCrossRef
34.
Zurück zum Zitat Sarica K, Erbağci A, Yağci F, Bakir K, Erturhan S, Uçak R (2004) Limitation of apoptotic changes in renal tubular cell injury induced by hyperoxaluria. Urol Res 32:271–277PubMedCrossRef Sarica K, Erbağci A, Yağci F, Bakir K, Erturhan S, Uçak R (2004) Limitation of apoptotic changes in renal tubular cell injury induced by hyperoxaluria. Urol Res 32:271–277PubMedCrossRef
Metadaten
Titel
The effect of calcium channel blockers on stone regrowth and recurrence after shock wave lithotripsy
verfasst von
Kemal Sarica
Yener İnal
Sakip Erturhan
Faruk Yağci
Publikationsdatum
01.06.2006
Verlag
Springer-Verlag
Erschienen in
Urolithiasis / Ausgabe 3/2006
Print ISSN: 2194-7228
Elektronische ISSN: 2194-7236
DOI
https://doi.org/10.1007/s00240-006-0040-x

Weitere Artikel der Ausgabe 3/2006

Urolithiasis 3/2006 Zur Ausgabe

Ambulantisierung: Erste Erfahrungen mit dem Hybrid-DRG

02.05.2024 DCK 2024 Kongressbericht

Die Hybrid-DRG-Verordnung soll dazu führen, dass mehr chirurgische Eingriffe ambulant durchgeführt werden, wie es in anderen Ländern schon länger üblich ist. Die gleiche Vergütung im ambulanten und stationären Sektor hatten Niedergelassene schon lange gefordert. Aber die Umsetzung bereitet ihnen doch Kopfzerbrechen.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Harninkontinenz: Netz-Op. erfordert über lange Zeit intensive Nachsorge

30.04.2024 Harninkontinenz Nachrichten

Frauen mit Belastungsinkontinenz oder Organprolaps sind nach einer Netz-Operation keineswegs beschwerdefrei. Vielmehr scheint die Krankheitslast weiterhin hoch zu sein, sogar höher als von harninkontinenten Frauen, die sich nicht haben operieren lassen.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.